骨髓瘤与DNA损伤
DNA损伤剂是首个对多发性骨髓瘤有效的治疗手段,临床应用65年后仍是主要疗法之一。骨髓瘤细胞增殖极慢,但自癌前阶段即存在广泛基因组重排和严重基因组不稳定。本文综述DNA损伤来源及DNA修复机制在骨髓瘤中的平衡,以及基于合成致死的新型治疗策略。
要点
- DNA损伤剂临床应用65年后仍是多发性骨髓瘤的主要治疗手段之一。
- 骨髓瘤细胞增殖极慢,但自癌前阶段即存在广泛基因组重排和严重基因组不稳定。
- 骨髓瘤中强效癌基因激活、蛋白酶体依赖生存和持续氧化应激共同调节DNA损伤与修复。
核心结论
- 靶向DNA损伤与修复在多发性骨髓瘤中始终居于核心地位,在可预见的未来仍将如此。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- DNA损伤剂自引入临床以来已65年,仍是多发性骨髓瘤的主要疗法之一。
- 骨髓瘤细胞增殖极慢,但自癌前阶段即呈现广泛基因组重排和强烈基因组不稳定。
- 骨髓瘤中激活的强效癌基因及浆细胞表型特征(包括依赖蛋白酶体生存和持续氧化应激)共同调节DNA损伤与修复。
- 骨髓瘤细胞在DNA修复机制保障生存与基因组不稳定之间维持 precarious 平衡。
- 利用骨髓瘤遗传病变或治疗所致同源重组缺陷,可设计更有效靶向骨髓瘤细胞的治疗组合,DNA损伤剂可能使细胞对免疫治疗敏感。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DNA-damaging agents have represented the first effective treatment for the blood cancer multiple myeloma, and after 65 years since their introduction to the clinic, they remain one of the mainstay therapies for this disease. Myeloma is a cancer of plasma cells. Despite exceedingly slow proliferation, myeloma cells present extended genomic rearrangements and intense genomic instability, starting at the premalignant stage of the disease. Where does such DNA damage stem from? A reliable model argues that the powerful oncogenes activated in myeloma as well the phenotypic peculiarities of cancer plasma cells, including the dependency on the proteasome for survival and the constant presence of oxidative stress, all converge on modulating DNA damage and repair. Beleaguered by these contraposing forces, myeloma cells survive in a precarious balance, in which the robust engagement of DNA repair mechanisms to guarantee cell survival is continuously challenged by rampant genomic instability, essential for cancer cells to withstand hostile selective pressures. Shattering this delicate equilibrium has been the goal of the extensive use of DNA-damaging agents since their introduction in the clinic, now enriched by novel approaches that leverage upon synthetic lethality paradigms. Exploiting the impairment of homologous recombination caused by myeloma genetic lesions or treatments, it is now possible to design therapeutic combinations that could target myeloma cells more effectively. Furthermore, DNA-damaging agents, as demonstrated in solid tumors, may sensitize cells to immune therapies. In all, targeting DNA damage and repair remains as central as ever in myeloma, even for the foreseeable future.
引用
- Tonon G. Myeloma and DNA damage. Blood. 2024. PMID: 37992215. doi:10.1182/blood.2023021384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。